Gene Expression Profiling in Patients with CML Experiencing Loss of Treatment Response
نویسندگان
1 Department of Biotechnology Khwaja Moinuddin Chishti Language University Lucknow, India.
2 Department of Biochemistry, Eras Lucknow Medical College and Hospital, Era University, Lucknow 226003, Uttar Pradesh, India.
3 Department of Biochemistry, Eras Lucknow Medical College and Hospital, Era University, Lucknow 226003, Uttar Pradesh, India.
4 Department of Biotechnology, Era’s Lucknow Medical College and Hospital Lucknow, India.
5 Department of Biotechnology, Era’s Lucknow Medical College and Hospital Lucknow, India.
6 Department of Biotechnology, Era’s Lucknow Medical College and Hospital Lucknow, India.
7 Department of Biotechnology, Era’s Lucknow Medical College and Hospital Lucknow, India.
8 Department of Biotechnology, Era’s Lucknow Medical College and Hospital Lucknow, India.
doi
چکیده
Chronic Myeloid Leukemia (CML) is a hematological malignancy characterized by the presence of the BCR-ABL1 fusion gene, which leads to uncontrolled proliferation of leukemic cells. Despite the effectiveness of Tyrosine Kinase Inhibitors (TKIs) such as imatinib, dasatinib, and nilotinib in controlling CML, treatment resistance remains a major clinical challenge. The mechanisms contributing ...
